During the intensive disclosure period of the semi-annual report in 2021, how is the performance of the pharmaceutical machinery industry?

[ Market Analysis of Chemical Machinery Equipment Network ] With the end of the first half of 2021, major listed companies have also entered a period of intensive disclosure of semi-annual reports
.
According to incomplete statistics, as of July 5, more than 600 A-share listed companies have released performance forecasts for the first half of 2021, and more than 60% of the companies are expected to have positive results, and many companies have increased their net profit by more than 10 times.
, companies with outstanding performance mainly focus on industries such as chemical industry, pharmaceuticals, integrated circuits, equipment manufacturing, and auto parts
.
Among the listed companies whose net profit is expected to double in the first half of the year, there are 26 equipment manufacturers
.
So, how did the pharmaceutical machine industry perform in the first half of this year?

Investors also expressed concern about the semi-annual performance of listed pharmaceutical machine companies
.
For example, an investor recently said to the domestic pharmaceutical machine giant Chutian Technology: "As of the 25th, one-third of the companies in the entire market have issued an announcement on the pre-increase in performance from January to June.
May I ask when the company will release the pre-increase in performance.
Announcement?” In response, the secretary of the Board of Directors of Chutian Technology replied that according to relevant rules, companies listed on the Growth Enterprise Market can decide whether to disclose the performance forecast according to the actual situation of the company
.

 

　　The author has learned that the current interim results of the pharmaceutical machine industry companies have only revealed the "tip of the iceberg".
For example, Jinlai Yingcai recently released the semi-annual performance forecast for 2021, and the performance is expected to rise in the same direction
.
During the reporting period, the company realized a net profit of 58 million yuan to 68 million yuan, an increase of 71.
82% to 101.
44% over the same period of the previous year; the profit of the same period last year was 33.
7572 million yuan
.
However, many listed pharmaceutical machine companies have already announced the time for the semi-annual report to be disclosed.
For example, Chutian Technology's 2021 semi-annual report is scheduled to be disclosed on August 28, 2021; Canaan Technology's 2021 semi-annual report is scheduled to be disclosed on August 28, 2021; Xinhua Medical's 2021 semi-annual report is scheduled to be disclosed on August 26, 2021; Xinlai Yingcai's 2021 semi-annual report is scheduled to be disclosed on August 24, 2021; Tofflon's 2021 semi-annual report is scheduled to be disclosed on August 23, 2021
.

 

　　Judging from the first quarter reports of 2021 disclosed by major listed pharmaceutical machine companies, most of the companies performed well
.
Among them, Chutian Technology’s 2021 first quarter report showed that the company’s main income was 1.
139 billion yuan, up 131.
28% year-on-year; net profit attributable to the parent was 105 million yuan, up 433.
14% year-on-year; net profit was 108 million yuan, up 392.
28% year-on-year; debt ratio was 55.
99 %, investment income of 200 million yuan, financial expenses of 100 million yuan, gross profit margin of 39.
56%; Tofflon's first quarter report in 2021 shows that the company achieved operating income of 717 million yuan, a year-on-year increase of 42.
36%; net profit attributable to shareholders of listed companies 110 million yuan, a year-on-year increase of 134.
28%, and earnings per share of 0.
18 yuan
.
During the reporting period, the company's gross profit margin was 43.
6%, an increase of 7.
8 percentage points year-on-year, and its net profit margin was 17%, an increase of 8.
3 percentage points year-on-year
.

 

　　From the perspective of the industry, the pharmaceutical equipment industry is ushering in a new round of prosperity, and the performance of industry companies is expected to improve
.
Since 2020, domestic pharmaceutical equipment production orders have ushered in a significant increase.
In the case of delayed delivery of imported equipment, local pharmaceutical machine manufacturers have gained opportunities, and the order volume has increased significantly.
The announcement stated that as of the end of the first quarter of 2021, the company had orders of about 5 billion yuan in hand; Jinlai Yingcai also stated on the interactive platform in June that the company's semiconductor industry products currently have sufficient orders in hand and production is very busy
.

 

　　At the same time, with the continuous growth of fixed assets investment in the pharmaceutical manufacturing industry, the income and profit of the pharmaceutical equipment industry have rebounded
.
Data show that as of the end of 2020, the total revenue of the pharmaceutical special equipment manufacturing industry was 19.
7 billion yuan, a year-on-year increase of 14.
6%; the total profit was 1.
275 billion yuan, a year-on-year increase of 145.
7%
.
Entering 2021, investment in the pharmaceutical manufacturing industry will continue to grow, of which only the investment in fixed assets from January to April will increase by 33.
1% year-on-year
.
The industry believes that China's pharmaceutical manufacturing industry is kicking off a new round of fixed asset investment upsurge, in this context, the pharmaceutical machine industry is expected to fully benefit
.

 

　　Since 2021, the development goals of pharmaceutical equipment enterprises have also become firmer
.
For example, Tofflon stated in its 2020 annual report that in 2021, the company will firmly focus on the development strategy of "systematization, internationalization, and digitalization", and will closely focus on the fields of pharmaceutical equipment such as sterile injections, bioengineering, APIs, and oral solids.
Focusing on the production process and development direction of drugs, research and develop innovative products with forward-looking and independent intellectual property rights
.
In the fields of cell preparation and food equipment, we will continue to invest in research and development and technical cooperation, improve the industrial layout, enrich the variety of products, stabilize and expand the market share
.
In 2021, the company's operating income target is to strive for 3.
5 billion yuan
.
In 2020, the company achieved operating income of 2.
708 billion yuan
.

 

　　In general, combined with the current 2021 first quarter reports of major pharmaceutical machine companies, the number of orders in hand, and the industry's prosperity, it is expected that many companies will be able to hand over a gratifying "semi-annual answer sheet"
.

 

　　Original title: During the intensive disclosure period of the semi-annual report in 2021, how is the performance of the pharmaceutical machinery industry?